Replies to post #243327 on Biotech Values

[mouton29]

Re ENTA: can you, or someone, provide some explanation or references to help translate this from the press release:

"...provided plasma drug levels that were 6-fold and 12-fold over the plasma protein adjusted EC90 for the Alpha variant and the Delta variant, respectively. "

It seems from this FDA document (https://www.fda.gov/media/71223/download) that EC90 its the effective concentration needed to inhibit viral replication by 90% but I'm not clear on how to apply that to the quoted sentence.

[vinmantoo]

ENTA's EDP-235 is plainly more potent than Paxlovid. And without the manifold drug-drug interactions consequent to ritonavir, EDP-235 should be considerably safer than Paxlovid too.

I agree. Good news indeed. I have relaxed a bit now but obviously a ways to go before EDP-235 hits the finish line yet. I assume ENTA won't announce a partnership deal for EDP-235 before phase II is completed but I have been wrong before.